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Abstract In this review we discuss cardiovascular mortality,
incidence and prevalence of heart disease, and cardiac interven-
tions and surgery in the Netherlands. We combined most re-
cently available data from various Dutch cardiovascular regis-
tries, Dutch Hospital Data (LMR), Statistics Netherlands
(CBS), and population-based cohort studies, to provide a broad
quantitative update. The absolute number of people dying from
cardiovascular diseases is declining and cardiovascular
conditions are no longer the leading cause of death in the
Netherlands. However, a substantial burden of morbidity per-
sists with 400,000 hospitalisations for cardiovascular disease
involving over 80,000 cardiac interventions annually. In the
Netherlands alone, an estimated 730,000 persons are currently
diagnosed with coronary heart disease, 120,000 with heart
failure, and 260,000 with atrial fibrillation. These numbers
emphasise the continuous need for dedicated research on pre-
vention, diagnosis, and treatment of heart disease in our country.
Keywords Cardiovascular disease .Mortality .Morbidity .
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Introduction
This manuscript provides an update on the current num-
ber of persons with cardiovascular and cardiac disease
manifestations in the Netherlands. Although the mortality from
cardiovascular disease (CVD) in our country has declined, its
disease burden remains high. Therefore, recent data on the
number of patients with specific clinical cardiac disease entities,
those having undergone surgical or percutaneous procedures, as
well as estimates of the number of hospitalisations for cardiac
reasons, are also given.
Data have been derived from various sources. Because it
was not possible to obtain information from the year 2012 in
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every instance, exact present-day numbers of procedures or
hospitalisations may be slightly dissimilar from those
provided herein. Still, we hope that our numbers will provide
some insight into the actual burden of heart disease in the
Netherlands and its management.
Cardiovascular mortality
Since its peak in the late 1950s (in women) and the early 1970s
(in men), cardiovascular mortality in the Netherlands has grad-
ually declined. This reduction has occurred despite the larger
number of elderly persons as well as the more advanced age of
contemporary Dutch citizens. After correction for these chang-
es (standardisation), the drop in cardiovascular mortality that
has taken place, a reduction of about 70 %, is considerable
[1, 2]. Cardiovascular mortality from 1950 to 2012 is delineat-
ed in Fig. 1. After 1980, the cardiovascular mortality rates in
women and men tend to converge [2].
Currently, CVD accounts for 27 % of all deaths. This
percentage was 33 % 10 years ago, 37 % in 1992 and between
45 and 50 % in earlier decades. In the year 2012, 39,048
persons (20,733 women and 18,315 men) died from a primary
cardiovascular cause (Table 1) [1]. The number of persons
dying from CVD amounted to 46,942 in 2003, and thus a drop
in absolute numbers of deaths from CVD has taken place
concomitantly with the relative decrease in fatal CVD.
Cardiovascular mortality as a fraction of total mortality in the
last 10 years is presented in Table 1. The specific causes of
cardiovascular mortality in the year 2012 are presented in
Table 2 [1].
Inspection of the data makes it clear that most cardiovascular
deaths result from atherosclerotic disease affecting the coronary,
cerebral, and other arterial vessels. Women die more often from
more ‘mature’ atherosclerotic manifestations such as stroke and
heart failure than men: the latter die in larger numbers from
myocardial infarction (MI). However, one should appreciate
that the primary cause of death is often difficult to ascertain and,
in particular in persons over 80 years of age, may not be
accurate [3, 4]. For instance, the number of 766 individuals
supposedly dying from infectious CVD could well be false,
since neither the incidence of bacterial endocarditis (estimated
to be approximately 300 cases per year in the Netherlands) nor
its clinical course (estimated case fatality less than 20 %) are
able to account for the numbers reported [5]. Although the
incidence of infective endocarditis has been stable in other parts
of Europe over the past decades [6], it must be noted that
contemporary data from the Netherlands are lacking.
On their own, atrial fibrillation (AF) and hypertension rep-
resent unlikely primary causes of death, yet thousands of deaths
are attributed to these morbid conditions. Also, the mortality
statistics combine causes and modes of death. For instance,
heart failure is not a disease entity in itself, but merely a
symptom of underlying cardiac conditions. Presumably many
more persons die from the consequences of heart failure [7], but
these deaths are attributed to for instance coronary, valvular, or
congenital heart disease. This is likewise also the case for
sudden cardiac death, which now only constitutes a minor part
of the cause of death statistics (‘Other heart diseases’ in
Table 2), whereas Dutch population-based studies have
demonstrated that approximately 10 % of all deaths in adults
fulfil the criteria for sudden cardiac death [8, 9].
Coronary heart disease
On the basis of estimates from registries in the general popu-
lation from 2007, 648,300 Dutch citizens had coronary heart
disease (CHD) (estimated prevalence in women 3 %, and 5 %
in men). Combined with the incidence of CHD in the same
year (82,100 persons), the total number of women and men
with CHDwas estimated to be 730,400. Of these, an estimated
298,100 had angina [2]. Although men and women are struck
Table 1 Total and cardiovascular mortality in the Netherlands from 2003
to 2012 (Source: Statistics Netherlands (CBS))
Year Cardiovascular
mortality
Non-cardiovascular
mortality
Total
N % N % N
2003 46,942 33 94,994 67 141,936
2004 44,638 33 91,915 67 136,553
2005 43,350 32 93,052 68 136,402
2006 41,720 31 93,652 69 135,372
2007 40,849 31 92,173 69 133,022
2008 40,129 30 95,007 70 135,136
2009 38,897 29 95,338 71 134,235
2010 39,009 29 97,049 71 136,058
2011 38,132 28 97,609 72 135,741
2012 38,371 27 102,442 73 140,813
Fig. 1 Standardised cardiovascular mortality per 100,000 inhabitants in
the Netherlands in women and men from 1950 to 2011 [2]
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by cerebrovascular disease at about the same age (data not
shown), women develop CHD disease approximately 10 years
later than their male counterparts (Fig. 2).
Myocardial infarction
In 2012, 3514men and 2681 women died from anMI (Tables 2
and 3).[1] Their absolute numbers in the years between 1980
and 2012 are presented in Table 3. MI-associated mortality
declined significantly by more than 70 % over time in both
men and women. Age-standardised mortality declined even
further. The number of hospitalisations for MI in 2012 was
20,025 in men and 9653 in women. Between 1980 and 2012,
the age-standardisedMI admission rate (year of standardisation:
2012) declined by 42 % in men and by 23 % in women.
However, the absolute number of hospitalisations for MI has
not changed much [1].
Significant discordance in mortality statistics based
on self-reports of hospitals (performance indicators) and data
from clinical registries is noted. Hospital mortality from
MI is between 5 and 10 % according to data from Statistics
Netherlands (CBS), with age being the main determinant
of adverse outcomes.
The incidence of first MI has been declining by about 3 to
4 % per year in the last decade, both in men and women. Total
incidence declined by 38 % in men and by 32 % in women
between 1998 and 2007 [10, 11].
Surgical procedures
The total number of surgical procedures, including paediatric
surgery, has gradually increased over the years to 17,293
operations in 2012, performed in 16 surgical centres (Fig. 3)
[1]. Seven percent of these interventions are ‘urgent’ (i.e. take
place before the start of the next working day after the decision
to operate has been taken) [12].
Table 2 Cardiovascular causes
of death in the Netherlands in
2012 (Source: Statistics
Netherlands (CBS)) [1]
Cause of death Men Women Total
N % N % N %
Ischaemic heart disease 5691 31 4029 19 9720 25
- Including myocardial infarction 3514 2681 6195
Cerebrovascular disease 3302 18 5222 25 8524 22
Congenital heart disease 64 <1 46 <1 110 <1
Rheumatic and valvular heart disease 698 4 1023 5 1721 4
Infectious heart disease 331 2 435 2 766 2
Other heart diseases 5778 32 7543 36 13,321 34
- Including heart failure 2625 4136 6761
- Including atrial fibrillation 538 939 1477
Arterial vascular disease 1067 6 714 3 1781 5
Atherosclerosis and/or hypertension 1023 6 1227 6 2250 6
Other vascular disease 361 2 494 2 855 2
Total 18,315 100 20,733 100 39,048 100
Fig. 2 Coronary heart disease incidence in men and women (per 1000
inhabitants) in the Netherlands in 2007 (Source: General practice registry) [2]
Table 3 Number of fatal myocardial infarctions in the Netherlands from
1980 to 2012, unstandardised (Source: Statistics Netherlands (CBS)) [1]
Year Men Women
N Per 100,000
inhabitants
N Per 100,000
inhabitants
1980 12,634 180 7718 108
1985 12,486 174 8082 110
1990 10,002 135 7300 97
1995 8888 116 6800 87
2000 7291 93 5668 70
2005 5361 66 4141 50
2010 3840 47 2983 36
2012 3514 42 2681 32
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About two-thirds of the 16,262 operations in adults in 2012
involved coronary artery bypass surgery (CABG), while half
of all surgical procedures are represented by isolated CABG
(source: Supervisory Committee for Cardiac Interventions in
the Netherlands (BHN)). In these procedures, the use of only
arterial grafts has increased from 15 % in 1995 to nearly 26 %
in 2011 [12]. The 30-day mortality of isolated CABG in 2010
was 1.2 % [1].
In 2012, a total of 3020 operations were related to diseases
of the aortic valve, and in 41 % of these procedures coronary
bypass grafts were implanted (source: Supervisory Committee
for Cardiac Interventions in the Netherlands (BHN)). The type
of prostheses implanted has gradually changed from mainly
mechanical prostheses in the 1990s to the use of bio-
prostheses in nearly 80 % of the operations nowadays. In
addition to CABG and aortic valve surgery, mitral valve
surgery is the most common indication for cardiac surgery
with approximately 1750 operations annually. Concomitant
CABG is performed in 36 % of these operations [1]. The
proportion of mitral valve repairs has increased to over
75 %. Active endocarditis is reported in less than 200 surgical
procedures per year [12]. Overall the 30-day mortality asso-
ciated with valvular surgery in 2010 was 3.6 % [1].
Mainly as a result of varying availability of donor
hearts, the number of yearly heart transplants has varied
considerably over the years. On average, about 40 to 50
transplants are performed each year in three academic
medical centres [13].
Other procedures include aortic surgery (approximately
1000 operations per year), transcatheter aortic valve implanta-
tion, and less frequently performed procedures such as surgical
left ventricle reconstruction, ventricular septal rupture repair,
rhythm surgery (as a concomitant or as a stand-alone
procedure), surgery for correction of congenital heart disease,
or management of cardiac trauma [14, 15].
Percutaneous coronary interventions
While the number of surgical procedures has only risen grad-
ually in the last decade, this has not been the case with the
percutaneous interventions (PCIs). Their number has risen
1995 2000 2005 2010
Percutaneous coronary interventions
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1983 1098
1984 1775
1985 8532 2556
1986 8693 3497
1987 9091 4556
1988 10798 5592
1989 11063 6809
1990 11936 7900
1991 11883 8780
1992 12644 10489
1993 12862 11466
1994 13812 12988
1995 14238 13284
1996 14545 14435
1997 14665 14723
1998 14586 15273
1999 14365 15713
2000 14439 17381
2001 14130 19444
2002 14251 21512
2003 14487 23813
2004 15640 28805
2005 15981 32198
2006 15796 33678
2007 16660 34685
2008 16914 36367
2009 16930 38591
2010 17426 39995
2011 17630 42123
2012 17293 45305
Percutaneous coronary interventions
Fig. 3 Number of surgical procedures and percutaneous coronary interventions in the Netherlands from 1983 to 2012 (Source: Supervisory Committee
for Cardiac Interventions in the Netherlands (BHN)) [1]
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much more quickly in recent years. For instance, in 2012,
45,305 PCIs were performed in 30 centres, and this number
represents more than a doubling of these procedures in a time
frame of only 10 years (Fig. 3) [1, 16]. The most frequent
indications for PCI were stable angina (42 %), acute MI
(33 %) and unstable angina (22 %). Over 90 % of the
procedures involved stent placement [13].
ICD and pacemaker implants
There has been a substantial increase in the number of im-
plantable cardioverter-defibrillator (ICD) implants in the last
10 years. Symptomatic patients with advanced heart failure
(e.g. left ventricular ejection fraction <30 %) are the main
recipients. Currently, their number is in the order of about
5000 new implants per year (Table 4). Registration of indica-
tions is not complete, but most (approximately 80 %) implants
are prophylactic, i.e. implanted in patients at high risk for sudden
cardiac death. The other patients receive an ICD after successful
resuscitation. In addition to the new ICD implants, their replace-
ment currently adds over 1000 procedures to the numbers pre-
sented in the table [13]. ICDs now have the ability to perform
biventricular pacing in patients with heart failure and conduction
abnormalities in order to emulate physiological cardiac function
(i.e. cardiac resynchronisation therapy). Biventricular systems
are becoming more popular and now account for almost 40 %
of all procedures. The average age of the patients is 66 years and
23 % of them are women. Relatively few (6 %) ICDs are
implanted beyond the age of 80 years.
Based on the Dutch ICD and Pacemaker Registry
(DIPR), an additional 10,389 pacemakers (excluding cardiac
resynchronisation therapy (CRT)) were implanted in 92 contrib-
uting hospitals in 2011. A fourth of the pacemaker implantations
were replacements of another device.
Heart failure
As with most other CVD, the presence of heart failure casts a
shadow over the last phase of life in a considerable number of
Dutch individuals. Between 20 and 30 % of the general
population will develop some form of heart failure, usually
when they are over 70 years of age [17]. Incidence rates in the
Netherlands increase steeply from about 1 per 1000 person-
years below 60 years of age to almost 50 per 1000 person-
years in those aged 90 years and over.
Due to the ageing of the population, an increase in the
number of patients with heart failure in the Netherlands was
already predicted in the 1990s [18]. Contemporary data have
confirmed that forecast, and an estimated 120,000 individuals
with heart failure, about 1 % of the adult Dutch population,
were reportedly present in 2008. The continuing ageing of the
population is expected to raise their numbers to an approxi-
mate 200,000 in the coming decade [19].
The majority of heart failure is diagnosed in chronic stages,
but episodes of acute cardiac decompensation can lead to
hospitalisation. In 2011, 29,916 hospital admissions were
registered in the Netherlands with heart failure as the primary
discharge diagnosis (source: Dutch Hospital Data (LMR))
[11]. The numbers are equally distributed over both sexes. This
number includes readmissions which are known to be frequent
in patients with heart failure. Recent Dutch data on the ratio of
first admissions to readmissions is lacking, but studies fromU.S.
registries consistently report 30-day readmission rates up to
25 % [20]. Between 1980 and 1990, the number of
hospitalisations for heart failure increased by about 50%. There-
after, a decrease was observed but, as of 2002, the number of
hospitalised patients increased again, although the total number
of days spent in hospital has more or less stabilised [19].
The prognosis of patients with heart failure has been de-
scribed as being more ‘malignant’ than that of many common
cancers [21]. Five-year survival after the initial diagnosis
ranges from approximately 25 to 35 % in population-based
studies [17]. The in-hospital mortality associated with decom-
pensated heart failure is poor, even for first occurrences, and
has been reported to be in the order of 15% in the Netherlands
[17]. This is worse than the currently observed in-hospital
mortality associated with acute MI.
The absolute number of Dutch citizens dying either fromMI
or heart failure has been depicted in Fig. 4, and clearly shows
the direction of the change in both causes of death. Since 2012,
the number of deaths from heart failure (n =6761) has surpassed
the mortality from MI (n =6195) (Table 2 and Fig. 4) [1].
Atrial fibrillation
AF is the most common sustained cardiac arrhythmia. The
condition carries serious health consequences, including
Table 4 Number of new ICD implants based on 29 centres in the
Netherlands from 2003 to 2012 (Source: Netherlands Heart Rhythm
Association (NHRA)) [13]
Year Non-CRT CRT Total
N % N % N
2003 800 82 180 18 980
2004 1237 79 327 21 1564
2005 1724 72 665 28 2389
2006 2005 67 967 33 2972
2007 2590 72 1030 28 3620
2008 2644 69 1175 31 3819
2009 2890 68 1385 32 4275
2010 2986 62 1804 38 4790
2011 3192 61 2007 39 5199
2012 3051 63 1830 37 4881
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increased risk for stroke and heart failure. AF is found to be
present in about a quarter of patients presenting with an
ischaemic stroke. The presence of many other cardio-
metabolic disorders, such as coronary and valvular heart
disease, cardiomyopathies, hypertension, and diabetes,
predispose to the development of AF.
Estimates from a Dutch population-based cohort study
indicate that the lifetime risk of AF is in the order of 20 to
25 %. As with heart failure, its occurrence strongly increases
with age: the incidence rate of AF below 60 years of age is less
than 1 per 1000 person-years, but rises to almost 20 per 1000
person-years in persons over 85 years of age [22]. These
estimates may underestimate the true incidence since the
presence of AF, either permanent or paroxysmal, may go
undetected clinically.
On the basis of the best available data, an estimated
260,000 Dutch individuals are currently affected by AF [23].
These were responsible for 42,188 hospital admissions in
2011 with AF as the primary discharge diagnosis (source:
Dutch Hospital Data (LMR)) [11]. Between 1994 and 2006,
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Myocardial Infarction    Heart failure
1980 20352 2661
1981 20721 2752
1982 20554 5727
1983 19869 6661
1984 20179 6220
1985 20568 5936
1986 19924 5101
1987 19045 3818
1988 18276 4027
1989 17547 4363
1990 17302 4432
1991 16988 4770
1992 16248 4892
1993 16955 7122
1994 15728 6726
1995 15688 6902
1996 15144 5272
1997 14200 5265
1998 14040 5322
1999 13401 5551
2000 12898 5908
2001 11858 5530
2002 11425 5598
2003 11250 5830
2004 9946 5624
2005 9445 5943
2006 8728 5952
2007 8126 6091
2008 7761 6237
2009 7071 6068
2010 6802 6424
2011 6467 6498
2012 6195 6761
Fig. 4 Number of deaths attributed to myocardial infarction or heart failure as the primary cause of death in the Netherlands from 1980 to 2012 (Source:
Statistics Netherlands (CBS))
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no major changes in its prevalence were observed but, given
current demographic developments, an increase in the number
of persons with AF in the coming years is projected [23].
Hospitalisations for cardiovascular disease
During the last years, the number of hospitalisations associat-
ed with CVD has stabilised at around 400,000 (2400 per
100,000 inhabitants). Almost 115,000 (29 %) of these com-
prise 1 day admissions related to diagnostic or therapeutic
procedures, or observations of cardiovascular symptoms. In
the remaining cases, the mean duration of hospital stay is
about 6 days (source: Statistics Netherlands (CBS)).
Admission rates for rhythm disturbances are on the rise [11].
Summary and conclusions
With plausible estimates of 730,000 patients with CHD, of
120,000 persons with heart failure, and of 260,000 men and
women with AF, the total count of Dutch individuals with some
manifestation of heart disease could be as high as one million.
In addition, a substantial number of women andmen have other
forms of atherosclerotic disease, either of the cerebral and/or the
peripheral arterial system. However, since atherosclerosis is
usually not limited to one organ system and many cardiac and
vascular diseases co-exist, the simple summation of the various
disease manifestations will likely overestimate the number of
individuals with cardiovascular and/or heart disease.
In view of the high CVD prevalence, it is striking that
actual mortality from CVD has declined so much. Currently,
27 % of all deaths result from CVD, and cancer has overtaken
CVD as the main cause of death in the Netherlands in both
women and men (source: Statistics Netherlands (CBS)). De-
spite substantial risk factor burden [24, 25], cardiovascular
mortality in the Netherlands is low in international
comparisons. The current Dutch age-standardised mortality
from circulatory disease is 147 per 100,000, and only Spain
and France have lower cardiovascular mortality rates (143 and
126 per 100,000, respectively). In all other European
countries, including for instance Switzerland and Greece,
cardiovascular mortality is higher [26].
The number of cardiac procedures in the Netherlands, in
particular that of PCI and CABG, is below the Organisation for
Economic Cooperation and Development (OECD) average. As
in most other European countries, the rate of PCI versus CABG
is in the order of 2.5. Both the numbers of percutaneous and
surgical cardiac procedures in the Netherlands are 50 % lower
than in our affluent neighbouring countries, Belgium
and Germany [26]. Patients with an acute MI are the main
PCI target population with about 13,000 procedures in 30,000
patients hospitalised for MI. The 15,000 PCIs performed for
stable angina constitute a relatively large proportion of PCI
procedures, although the large number of patients with angina
in the population must be taken into account.
Throughout our review we have cited various sources from
which we obtained data on CVD in the Netherlands. However,
data from different sources can be conflicting due to differential
participation of hospitals in registries or due to the outcome
definitions used. As an example, cardiovascular mortality is
defined differently in the statistical updates from theDutchHeart
Foundation [10] compared to Statistics Netherlands (CBS). This
results in minor discrepancies in the annual number of deaths
attributable to CVD, in this case related to the inclusion or
exclusion of congenital and perinatal heart disease and vascular
autoimmune disorders (e.g. Table 1 and 2).
Future projections are always fraught with uncertainty, but
demographic trends undeniably suggest an increase in the
number of patients with heart disease and other forms of
CVD in the not too distant future. Still, these trends are not
dissimilar to the circumstances observed in the last decades,
during which time cardiovascular mortality decreased so
markedly. Most likely, these developments will continue,
and high morbidity (and high prevalence) but relatively low
mortality from CVD remains the most plausible scenario for
the foreseeable future.
Acknowledgments The authors gratefully acknowledge the Dutch
ICD and Pacemaker Register (DIPR), the National Cardiovascular Data
Registry (NCDR), the Adult Cardiac Surgery Database of the
Netherlands Association for Cardio-Thoracic Surgery (NVT) [15], and
the Supervisory Committee for Cardiac Interventions in the Netherlands
(Begeleidingscommissie Hartinterventies Nederland (BHN)) for their
willingness to provide data on cardiac interventions.
We thank the working group ‘Cijfers’ from the Dutch Heart Foundation
for their willingness to share the data on the 2012 cardiovascular mortality
and cardiac interventions prior to the release of the annual publication on the
burden of CVD in the Netherlands (see http://www.hartstichting.nl/
professionals/cijfers/cijfers/) [1].
Funding None.
Potential conflict of interest All authors have completed and submitted
the ICMJE ‘Form for Disclosure of Potential Conflicts of Interest’.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Vaartjes I, Koopman C, van Dis I, et al. Hart- en vaatziekten in
Nederland 2013, cijfers over leefstijl, risicofactoren, ziekte en sterfte.
The Hague: Dutch Heart Foundation; 2013.
2. National Institute for Public Health and the Environment (RIVM).
National Public Health Compass. 2013 [November 19, 2013];
Neth Heart J (2014) 22:3–10 9
Available from: http://www.nationaalkompas.nl/gezondheid-en-
ziekte/ziekten-en-aandoeningen/hartvaatstelsel/
3. Ives DG, Samuel P, Psaty BM, et al. Agreement between nosologist
and cardiovascular health study review of deaths: implications of
coding differences. J Am Geriatr Soc. 2009;57:133–9.
4. Kelson M, Farebrother M. The effect of inaccuracies in death certi-
fication and coding practices in the European Economic Community
(EEC) on international cancer mortality statistics. Int J Epidemiol.
1987;16:411–4.
5. van der Meer JTM, Thompson J, Valkenburg HA, et al.
Epidemiology of bacterial endocarditis in the Netherlands. I.
Patient characteristics. Arch Intern Med. 1992;152:1863–8.
6. Moreillon P, Que YA. Infective endocarditis. Lancet. 2004;363:
139–49.
7. Engelfriet PM, Hoogenveen RT, Boshuizen HC, et al. To die with or
from heart failure: a difference that counts: is heart failure underrepre-
sented in national mortality statistics? Eur J Heart Fail. 2011;13:377–83.
8. Straus SMJM, Bleumink GS, Dieleman JP, et al. The incidence of
sudden cardiac death in the general population. J Clin Epidemiol.
2004;57:98–102.
9. Straus SMJM, Kors JA, De Bruin ML, et al. Prolonged QTc interval
and risk of sudden cardiac death in a population of older adults. J Am
Coll Cardiol. 2006;47:362–7.
10. Koopman C, Bots ML, van Oeffelen AAM, et al. Population trends
and inequalities in incidence and short-term outcome of acute myocar-
dial infarction between 1998 and 2007. Int J Cardiol. 2013;168:993–8.
11. Koopman C, van Dis I, Visseren FLJ, et al. Hart- en vaatziekten in
Nederland 2012, cijfers over risicofactoren, ziekte en sterfte. The
Hague: Dutch Heart Foundation; 2012.
12. Board of the Netherlands Association for Cardio-Thoracic Surgery.
De Nederlandse dataregistratie hartchirurgie: resultaten van
samenwerking tussen 16 Nederlandse hartchirurgische centra.
Utrecht: Netherlands Association for Cardio-Thoracic Surgery
(NVT); 2012 [November 19, 2013]; Available from: http://www.
nvtnet.nl/index.asp?news_id=113&category_id=0
13. Vaartjes I, van Dis I, Visseren FLJ, et al. Hart- en vaatziekten in
Nederland 2011, cijfers over leefstijl- en risicofactoren, ziekte en
sterfte. The Hague: Dutch Heart Foundation; 2011.
14. Siregar S. Safety in cardiac surgery [PhD thesis, Utrecht University,
Utrecht, the Netherlands]. Enschede: Gildeprint Drukkerijen; 2013
[November 19, 2013]; Available from: http://igitur-archive.library.
uu.nl/dissertations/2013-0612-200800/UUindex.html
15. Siregar S, Groenwold RHH, Versteegh MIM, et al. Data resource
profile: adult cardiac surgery database of the Netherlands association
for cardio-thoracic surgery. Int J Epidemiol. 2013;42:142–9.
16. de Winter RJ. Percutaneous coronary intervention without surgery
on-site is here to stay. Neth Heart J. 2013;21:446–8.
17. Bleumink GS, Knetsch AM, SturkenboomMCJM, et al. Quantifying
the heart failure epidemic: prevalence, incidence rate, lifetime risk
and prognosis of heart failure the Rotterdam study. Eur Heart J.
2004;25:1614–9.
18. Bonneux L, Barendregt JJ, Meeter K, et al. Estimating clinical
morbidity due to ischemic heart disease and congestive heart
failure: the future rise of heart failure. Am J Public Health.
1994;84:20–8.
19. Engelfriet PM, Hoogenveen RT, Poos MJJC, et al. Hartfalen:
epidemiologie, risicofactoren en toekomst. Bilthoven: National
Institute for Public Health and the Environment (RIVM); 2012
[November 19, 2013]; Available from: http://www.rivm.nl/
bibliotheek/rapporten/260401006.html
20. Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and timing
of 30-day readmissions after hospitalization for heart failure, acute
myocardial infarction, or pneumonia. JAMA. 2013;309:355–63.
21. Stewart S, MacIntyre K, Hole DJ, et al. More ‘malignant’ than
cancer? Five-year survival following a first admission for heart
failure. Eur J Heart Fail. 2001;3:315–22.
22. Heeringa J, van der Kuip DAM, Hofman A, et al. Prevalence,
incidence and lifetime risk of atrial fibrillation: the Rotterdam study.
Eur Heart J. 2006;27:949–53.
23. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of
individuals with atrial fibrillation in the European Union, from 2000
to 2060. Eur Heart J. 2013;34:2746–51.
24. Soedamah-Muthu SS, Geleijnse JM, Giltay EJ, et al. Levels and
trends in cardiovascular risk factors and drug treatment in 4837
elderly Dutch myocardial infarction patients between 2002 and
2006. Neth Heart J. 2012;20:102–9.
25. van Dis I, Geleijnse JM, Verschuren WMM. Cardiovascular risk
management of hypertension and hypercholesterolaemia in the
Netherlands: from unifactorial to multifactorial approach. Neth
Heart J. 2012;20:320–5.
26. World Health Organization. The European health report 2012: charting
the way to well-being. Copenhagen: World Health Organization; 2013
[November 19, 2013]; Available from: http://www.euro.who.int/en/
data-and-evidence/european-health-report-2012
10 Neth Heart J (2014) 22:3–10
